Immunovant (IMVT) Q2 2025 earnings summary

Executive summary

• IMVT-1402 advanced with five INDs cleared across multiple therapeutic areas, enabling rapid progression toward pivotal trials in Graves' disease and difficult-to-treat rheumatoid arthritis by March 2025, exceeding internal goals.

• Phase 1 data for IMVT-1402 showed deep, dose-dependent IgG suppression (>70-80%) with subcutaneous dosing and minimal impact on analytes, supporting a best-in-class profile.

• Batoclimab continues in Phase 3 trials for myasthenia gravis, thyroid eye disease, and CIDP, with top-line data expected by March 31, 2025; IMVT-1402 development leverages batoclimab data and competitor insights.

• Melanie Gloria appointed Chief Operating Officer, bringing extensive late-stage drug development experience.

Financial highlights

• Net loss for Q2 FY2024 was $109.1 million ($0.74/share), up from $58.7 million ($0.45/share) in Q2 FY2023, driven by increased R&D and G&A expenses.

• Cash and cash equivalents totaled $472.9 million as of September 30, 2024, supporting ongoing and planned clinical development.

• R&D expenses for the quarter were $97.3 million, up $49.3 million year-over-year, mainly due to IMVT-1402 trial preparations and higher batoclimab clinical costs.

• No product revenue generated; company remains reliant on equity financing and has not issued any ATM shares under its $150 million program.

Outlook and guidance

• On track to initiate four to five potentially registrational trials with IMVT-1402 by March 31, 2025, and clinical trials in ten indications by March 31, 2026.

• Top-line data from batoclimab trials in MG and CIDP expected by March 31, 2025; TED trial data expected in H2 2025.

• Existing cash is expected to fund operations for at least the next 12 months and into the long term.